Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression.

Saved in:
Bibliographic Details
Title: Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression.
Authors: Alzofon N; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado, Aurora, Colorado., Koc K; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado, Aurora, Colorado., Panwell K; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado, Aurora, Colorado., Pozdeyev N; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado, Aurora, Colorado.; Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado, Aurora, Colorado., Marshall CB; Department of Pathology, University of Colorado, Aurora, Colorado., Albuja-Cruz M; Division of Trauma, GI and Endocrine Surgery, Department of Surgery, University of Colorado, Aurora, Colorado., Raeburn CD; Division of Trauma, GI and Endocrine Surgery, Department of Surgery, University of Colorado, Aurora, Colorado., Nathanson KL; Department of Medicine, Translational Medicine Division and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania., Cohen DL; Renal and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Wierman ME; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado, Aurora, Colorado.; Research Service, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado., Kiseljak-Vassiliades K; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado, Aurora, Colorado.; Research Service, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado., Fishbein L; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado, Aurora, Colorado. lauren.fishbein@cuanschutz.edu.; Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado, Aurora, Colorado.
Source: Molecular cancer research : MCR [Mol Cancer Res] 2021 Sep; Vol. 19 (9), pp. 1476-1485. Date of Electronic Publication: 2021 May 13.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101150042 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3125 (Electronic) Linking ISSN: 15417786 NLM ISO Abbreviation: Mol Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3125
DOI:10.1158/1541-7786.MCR-20-0992